Muscle Wasting Explained: Atrophy, Anabolic Resistance and the Myostatin Pathway

Muscle wasting is the loss of skeletal muscle that happens when protein breakdown outpaces protein synthesis for long enough that muscle fibres shrink. It follows immobilization, accompanies aging as sarcopenia and cancer as cachexia, and in animal models the same molecular switches recur across many causes. Those switches, from the MuRF1 and atrogin-1 ligases to myostatin and IGF-1, are the readouts and targets of laboratory atrophy models.

This guide defines the three forms, explains the pathways behind them, covers anabolic resistance and measurement, and separates drugs in trials from research reagents.

What muscle wasting is

Skeletal muscle is the body’s main protein reservoir, its proteins constantly turning over. Muscle mass holds steady while synthesis and breakdown balance; muscle wasting is what happens when the balance stays negative, and muscle atrophy is the cell-level result: fibres lose protein and shrink.

Which side moves depends on the cause. Reviewing immobilization studies in people, a group led from McMaster University in Hamilton, Ontario, concluded that most of the loss comes from a fall in synthesis, fasted and fed, with no clear rise in breakdown, and that cell and animal studies give different results. Rodent and cell models show a sharp rise in breakdown machinery, the source of most molecular findings below.

Atrophy, sarcopenia and cachexia

Disuse atrophy

Disuse atrophy follows unloading, and it is fast. When 24 healthy young men had one leg in a full-leg cast, quadriceps cross-sectional area fell 3.5% in five days and 8.4% in 14 days, and strength fell 9% and 23%. In the McMaster study, ten healthy adults averaging 72 years cut their daily steps by about three-quarters for 14 days and lost about 3.9% of leg fat-free mass.

Sarcopenia

The European Working Group on Sarcopenia in Older People revised its definition in 2019 (EWGSOP2): a progressive, generalized skeletal muscle disorder, rooted in changes that accumulate over a lifetime and associated with falls, fractures, physical disability and mortality. Low strength makes sarcopenia probable, low muscle quantity or quality confirms it, and poor physical performance makes it severe.

Cachexia

A 2011 international consensus defined cancer cachexia as ongoing skeletal muscle loss, with or without loss of fat mass, that conventional nutritional support cannot fully reverse and that progressively impairs function. Its criterion is a loss of more than 5% of body weight over six months, or more than 2% when body-mass index or muscle mass is already low, and it recognizes three stages: precachexia, cachexia and refractory cachexia. Two of its 19 authors, Vickie Baracos and Robin Fainsinger, were at the University of Alberta.

How muscle protein is broken down

Breakdown in atrophying muscle runs through the ubiquitin–proteasome system, in which ubiquitin ligases tag proteins for the proteasome, and the autophagy–lysosome system, which delivers larger structures to lysosomes.

The atrogenes: MuRF1 and atrogin-1

In 2001 Bodine and colleagues profiled gene expression across rat atrophy models and found only a small subset of genes raised in all of them. Two encoded ubiquitin ligases, Muscle RING Finger 1 (MuRF1) and Muscle Atrophy F-box (MAFbx, also called atrogin-1). Overexpressing MAFbx made cultured myotubes atrophy, and mice lacking either ligase resisted atrophy. A 2021 review still calls them the master genes of muscle atrophy, part of a wider set of atrophy genes known as atrogenes.

FoxO and autophagy

FoxO transcription factors link growth signalling to these genes. When cultured myotubes atrophy, PI3K–Akt activity falls and FoxO becomes active; constitutively active FoxO3 switches on atrogin-1 and causes marked atrophy of myotubes and muscle fibres, while IGF-1 or extra Akt suppresses both FoxO activity and atrogin-1. FoxO3 also drives autophagy genes, and blocking FoxO spares muscle in several rodent catabolic models.

Glucocorticoids and cytokines

Glucocorticoids such as cortisol (see our ACTH and HPA axis guide) push both sides at once: they speed breakdown and suppress synthesis, partly by inducing REDD1, which inhibits mTOR, and KLF15, and they raise FoxO and myostatin expression. Fast-twitch fibres are the most sensitive, and MuRF1-knockout and myostatin-knockout mice resist glucocorticoid-induced atrophy.

Tumour necrosis factor alpha (TNF-α) and interleukin-6 drive wasting partly through NF-κB and STAT3: overexpressing IKKβ, which switches NF-κB on, causes wasting in mice that depends partly on MuRF1, and inhibiting STAT3 spares muscle in tumour-bearing mice. See NF-κB explained and our guide to inflammatory mediators.

Myostatin, activins and follistatin

Myostatin, described in 1997 as growth/differentiation factor-8 (GDF-8), is a TGF-β family member expressed in developing and adult skeletal muscle. In mice lacking it, individual muscles weigh two to three times more than normal, from both more fibres (hyperplasia) and larger ones (hypertrophy). In people, myostatin mRNA doubled within five days in the cast study above.

Mature myostatin, a disulfide-linked dimer held in a complex with its propeptide, binds activin type II receptors, mainly ActRIIB. These recruit the type I receptors ALK4 or ALK5, which phosphorylate Smad2 and Smad3, and these partner with Smad4. Activins use the same receptors, and in animal studies inhibiting Smad2/3 alone enlarges muscle; rapamycin, by blocking mTOR, reverses the enlargement seen when myostatin is blocked.

Follistatin

Follistatin is a secreted protein that binds myostatin and blocks it from reaching ActRIIB. In 2001 Lee and McPherron showed that mice made to express follistatin, the myostatin propeptide or a dominant-negative ActRIIB in muscle ended up with dramatically larger muscles, much like myostatin knockouts. Follistatin also stimulates the BMP–Smad1/5/8 branch that helps maintain muscle mass, so its effect is not only myostatin blockade.

The anabolic arm: IGF-1, Akt and mTOR

Insulin-like growth factor 1 (IGF-1) works the other way. Its receptor activates PI3K and Akt; Akt activates mTORC1, which drives protein synthesis through targets such as S6K1 (p70S6K) and 4E-BP1. In animal muscle, constitutively active Akt causes striking fibre enlargement, and the mTOR inhibitor rapamycin prevents enlargement under anabolic conditions. Because Akt also holds FoxO back, the signal that builds protein suppresses the atrogenes. See what IGF-1 is and mTOR explained.

Anabolic resistance

Anabolic resistance is a blunted rise in muscle protein synthesis in response to a stimulus that normally switches it on, usually amino acids or a meal. In a 2005 study of 44 healthy men, resting synthesis did not differ by age, but older muscle was less sensitive and less responsive to essential amino acids, even with insulin held at basal levels, and showed lower expression and activation of mTOR, p70S6K, 4E-BP1 and eIF2B, with more NF-κB.

Inactivity produces the same picture quickly. In the McMaster step-reduction study, fasting synthesis did not change, but fed-state myofibrillar protein synthesis fell by about 26% and fed-state insulin sensitivity by about 43%. For laboratory models, the lesson is that resting measurements can miss the defect; it appears when the system is stimulated.

How muscle wasting is measured in research

Studies combine measures of muscle quantity, strength and turnover.

In 2008 a University of Alberta team in Edmonton showed that muscle and fat measured at the third lumbar vertebra on routine cancer-care CT images strongly predicted whole-body fat and fat-free mass in 50 patients (r = 0.86–0.94). D3-creatine dilution reads a deuterium-labelled creatine tracer as D3-creatinine in urine by liquid chromatography–mass spectrometry (see our LC-MS explainer), and deuterium oxide labels body water so synthesis can be followed for days.

Drugs in trials and research peptides

Several of these pathways are now drug targets, tested in regulated trials (see clinical trial phases explained); research peptides are laboratory reagents.

Myostatin and activin blockers

Bimagrumab is an antibody that blocks activin type II receptor signalling. In a six-month trial in 180 adults aged 70 or older with sarcopenia, both groups also following a diet and home-exercise program, lean body mass rose 7% with bimagrumab and 1% with placebo, but physical function improved in both groups with no significant difference.

Apitegromab, an antibody that binds the pro- and latent forms of myostatin to block its activation, won US Food and Drug Administration approval on September 11, 2026, as Isembyld, for spinal muscular atrophy in people aged two and older already receiving an SMN2-targeted medicine. In its 52-week trial, 34.2% of children aged 2 to 12 on apitegromab reached a clinically meaningful motor-score gain against 13.5% on placebo; the FDA notes a higher fracture risk.

Follistatin gene transfer

In a phase 1/2a trial, six patients with Becker muscular dystrophy received an AAV1 vector carrying the FS344 form of follistatin into both quadriceps. Four walked further on the six-minute walk test, by 29 to 125 metres, and two did not; the authors framed it as a proof-of-principle study.

Ghrelin-receptor agonists

Anamorelin, a ghrelin-receptor agonist thought to raise appetite and serum IGF-1, was approved in Japan in December 2020 for cancer cachexia in non-small cell lung, gastric, pancreatic and colorectal cancer. In 2017 the European Medicines Agency recommended refusing marketing authorization: two main studies in about 1,000 people with lung cancer showed a marginal effect on lean body mass and no proven effect on handgrip strength or quality of life, and safety data had not been recorded adequately. See ghrelin explained.

Where research peptides fit

GHRP-2 and hexarelin are synthetic growth hormone secretagogues that act on the ghrelin receptor (see what a secretagogue is and GHRP-6 vs GHRP-2 vs hexarelin):

• GHRP-2 (rat study). In rats with adjuvant-induced arthritis, eight days of GHRP-2 kept muscle MuRF1, MAFbx and TNF-α mRNA from rising and raised serum IGF-1; the endpoints were gene expression, not function.
• Hexarelin (rat study). In rats given the chemotherapy drug cisplatin, hexarelin and a second secretagogue, JMV2894, prevented abnormal calcium handling in a fast-twitch muscle and improved several atrophy measures.
• IGF-1 LR3 (cell culture). This long analogue, with an N-terminal extension and arginine at position 3, binds IGF-binding proteins weakly; in L6 rat myoblasts the long analogues were more potent than IGF-1 at stimulating DNA synthesis and inhibiting protein breakdown. See our IGF-1 LR3 guide.

These are rodent and cell results; they do not show an effect on muscle in people.

What’s established and what isn’t

Sourcing muscle-research peptides in Canada

Muscle-cell and receptor assays are only as good as the reagent. When buying research peptides in Canada for this work:

• Ask for a batch-matched certificate showing identity by mass spectrometry and purity by HPLC, and check the batch number against the vial; see our COA guide.
• Match the reagent to the model. IGF-1 LR3’s weak binding to IGF-binding proteins makes it behave differently from native IGF-1 in culture.
• Plan controls, including a vehicle and, where possible, a scrambled-sequence peptide.
• Store lyophilized material cold, dry and dark; see the peptide storage guide.

GHRP-2Ghrelin-receptor agonist used in rodent muscle studiesView product HexarelinGhrelin-receptor agonist used in a rat cisplatin modelView product IGF-1 LR3Long IGF-1 analogue used in cell cultureView product

Frequently asked questions